Skip to main content
SpringerLink
Log in

The Relationship of Antipsychotic Medication Class and Adherence with Treatment Outcomes and Costs for Florida Medicaid Beneficiaries with Schizophrenia

  • Original Paper
  • Published:
Administration and Policy in Mental Health and Mental Health Services Research Aims and scope Submit manuscript

Abstract

While some studies show a significant advantage in adherence rates with use of atypical versus typical antipsychotic medication, others show no advantage or mixed results (Jones et al. (2006). Archives of General Psychiatry, 63, 1079–1087; Rosenheck, (2006). Archives of General Psychiatry, 63, 1074–1076). This study examined treatment outcomes and costs associated with adherence rates by antipsychotic medication class for adult Medicaid beneficiaries in Florida diagnosed with schizophrenia. Outcomes examined include arrests, involuntary commitments, and physical and behavioral healthcare costs. Study findings demonstrate that medication adherence for persons with schizophrenia may be as important to treatment costs and benefits as the class of medication used.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005). Remission in schizophrenia: Proposed criteria and rationale for consensus. American Journal of Psychiatry, 162, 441–449.

    Article  PubMed  Google Scholar 

  • Awad, A. G., & Voruganti, L. N. (2004). New antipsychotics, compliance, quality of life, and subjective tolerability—Are patients better off? Canadian Journal of Psychiatry, 49(5), 297–302.

    Google Scholar 

  • Baker, F. M., & Bell, C. (1999). Issues in the psychiatric treatment of African Americans. Psychiatric Services, 50(3), 362–350.

    PubMed  CAS  Google Scholar 

  • Becker, M., & Diamond, R. (2005). Quality of life measurement in persons with schizophrenia: Are we measuring what’s important? In H. Katschnig & H. Freeman (Eds.), Quality of life in mental disorders (2nd ed.). Chichester, England: Wiley.

    Google Scholar 

  • Becker, M., Jang, Y., & Kane, M. (2006). Evaluation of Florida Medicaid behavioral health pharmacy practice by racial/ethnic minorities across the lifespan (pp. 1–27). Tampa, FL: Louis de la Parte Florida Mental Health Institute, University of South Florida.

    Google Scholar 

  • Becker, M., & Lemrow, N. (2004). Behavioral health care services associated with switching atypical antipsychotic medication for persons with SMI (pp. 1–76). Tampa, FL: Louis de la Parte Florida Mental Health Institute, University of South Florida.

    Google Scholar 

  • Boyd, D. L. (2003). The bursting State Fiscal Bubble and State Medical Budgets. Health Affairs, 22(1), 46–61.

    Article  PubMed  Google Scholar 

  • Brown, C., Markowitz, J., Moore, T., & Parker, N. (1999). Atypical antipsychotics, part II: Adverse effects, drug interactions, and costs. Annals of Pharmacotherapy, 33, 210–217.

    Article  PubMed  CAS  Google Scholar 

  • Csernansky, J. G., & Schuchart, E. K. (2002). Relapse and rehospitalisation rates in patients with schizophrenia: Effects of second generation antipsychotics. CNS Drugs, 16, 473–484.

    Article  PubMed  Google Scholar 

  • Daumit, G. L., Crum, R. M., Guallar, E., et al. (2003). Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and Whites in the United States. Archives of General Psychiatry, 60, 121–128.

    Article  PubMed  Google Scholar 

  • Davis, J. M., Chen, N., & Glick, I. D. (2003). A meta-analysis of the efficacy of second generation antipsychotics. Archive of General Psychiatry, 60, 553–564.

    Article  CAS  Google Scholar 

  • Dolder, C. R., Lacro, J. P., Dunn, L. B., et al. (2002). Antipsychotic medication adherence: Is there a difference between typical and atypical agents? American Journal of Psychiatry, 159, 103–108.

    Article  PubMed  Google Scholar 

  • Dolder, C. R., Lacro, J. P., & Jeste, D. V. (2003). Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders. Psychosomatic Medicine, 65, 156–162.

    Article  PubMed  Google Scholar 

  • Eaddy, M., Grogg, A., & Locklear, J. (2005). Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clinical Therapeutic, 27(2), 263–272.

    Article  Google Scholar 

  • Fenton, W. S., Blyler, C. R., & Heinssen, R. K. (1997). Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophrenia Bulletin, 23(4), 637–651.

    PubMed  CAS  Google Scholar 

  • Fichtner, C. G., Hanrahan, P., & Luchins, D. J. (1998). Pharmacoeconomic studies of atypical antipsychotics: Review and perspective. Psychiatric Annals, 28(7), 381–396.

    Google Scholar 

  • Foster, R. H., & Goa, K. L. (1999). Olanzapine: A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics, 15, 611–640.

    Article  PubMed  CAS  Google Scholar 

  • Gardner, J. C., Luo, Z., Bradley, C. J., Polverrjan, E., Holmes-Rovnes, M., & Rovner, D. (2003). Longitudinal assessment of cost in health care intervention. Health Services Research Methodology, 3, 149–168.

    Article  Google Scholar 

  • Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000). Atypical antipsychotics in treatment of schizophrenia: Systematic overview and meta-regression analysis. British Nursing Journal, 321, 1371–1376.

    CAS  Google Scholar 

  • Gibson, J., Damler, R., Jackson, A. E., Wilder, T., & Ramsey, J. L. (2004). The impact of olanzapine, risperidone, or haldol on the cost of schizophrenia care in a Medicaid population. Value in Health, 7(1), 22–35.

    Article  PubMed  Google Scholar 

  • Glazer, W. M. (1998). Formulary decisions and health economics. Journal of Clinical Psychiatry, 59(Suppl. 19), 23–29.

    PubMed  Google Scholar 

  • Hargraves, W. A., & Shumway, M. (1996). Pharmacoeconomics of antipsychotic drug therapy. Journal of Clinical Psychiatry, 57(Suppl. 9), 66–76.

    Google Scholar 

  • Haynes, R. B. (1979). Introduction. In R. B. Haynes, D. L. Sackett, & D. W. Taylor (Eds.), Compliance in health care (pp. 1–10). Baltimore, MD: John Hopkins University Press.

    Google Scholar 

  • Herbeck, D. M., West, J. C., Ruditis, I., et al. (2004). Variations in use of second-generation antipsychotic medication by race among adult psychiatric patients. Psychiatric Services, 55, 677–684.

    Article  PubMed  Google Scholar 

  • Hogan, M. F. (1999). Public-sector mental health care: New challenges. Health Affairs, 18, 106–111.

    Article  PubMed  CAS  Google Scholar 

  • Javaid, J. I., Holland, D., & Janicak, P. G. (1991). Blood level monitoring of antipsychotics and antidepressants. Psychiatric Medicine, 9(1), 163–187.

    PubMed  CAS  Google Scholar 

  • Jones, K., Chen, H. J., Jordan, N., Boothroyd, R. A., Ramoni-Perazzi, J., & Shern, D. L. (2006). Examination of formal treatment costs in the provision of managed care for a Medicaid population with psychiatric disabilities. Medical Care, 44, 320–327.

    Article  PubMed  Google Scholar 

  • Jones, P., Barnew, T., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K., Murray, R., Markwick, A., & Lewis, S. (2006). Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Archives of General Psychiatry, 63, 1079–1087.

    Article  PubMed  CAS  Google Scholar 

  • Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. Journal of Clinical Psychiatry, 63(10), 892–909.

    PubMed  Google Scholar 

  • Lehman, A. F., & Steinwachs, D. M. (1998). Translating research into practice: the schizophrenia patient outcomes research team (PORT) treatment recommendations. Schizophrenia Bulletin, 24, 1–10.

    PubMed  CAS  Google Scholar 

  • Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R., Perkins, D., Keefe, R., Davis, S., Davis, C., Lebowitz, B., Severe, J., & Hsiano, J. (2005). Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with schizophrenia. New England Journal of Medicine, 353, 1209–1223.

    Article  PubMed  CAS  Google Scholar 

  • McCombs, J. S., Nichol, M. B., Johnstone, B. M., Stimmel, G. L., Shi, J., & Smith, R. (2000). Antipsychotic drug use patterns and the cost of treating schizophrenia. Psychiatric Services, 51(4), 525–527.

    Article  PubMed  CAS  Google Scholar 

  • Mojtabai, R., Lavelle, J., Gibson, P.J., et al. (2002). Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989–1996. Psychiatric Services, 53(3), 337–339.

    Article  PubMed  Google Scholar 

  • Moy, E., Dayton, E., & Clancy, C. M. (2005). Compiling the evidence: The national healthcare disparities reports. Public Response, March/April, pp. 376–386.

  • Naber, D., Moritz, S., Lambert, M., et al. (2001). Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophrenia Research, 50, 79–88.

    Article  PubMed  CAS  Google Scholar 

  • Nicole, L. (2005). Health disparities—Less talk more action. New England Journal of Medicine, 35(7), 727–729.

    Google Scholar 

  • Olivieri, N., Matsui, D., Hermann, C., & Koren, G. (1991). Compliance assessed by the medication event monitoring system. Archives of Disease in Childhood, 66, 1399–1402.

    Article  PubMed  CAS  Google Scholar 

  • Pandiana, J. A., & Banks, S. M. (2003). Large data sets are powerful. Psychiatric Services, 54, 745.

    Article  Google Scholar 

  • Ren, X. S., Kazia, L. E., Lee, A. F., et al. (2002). Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia. Journal of Pharmacy and Therapeutics, 27, 441–451.

    Article  CAS  Google Scholar 

  • Rice, D. P. (1999). The economic impact of schizophrenia. Journal of Clinical Psychiatry, 60(Suppl. 1), 4–6.

    PubMed  Google Scholar 

  • Rittmannsberger, H., Pachinger, T., Keppelmuller, P., & Wancata, J. (2004). Medication adherence among psychotic patients before admission to inpatient treatment. Psychiatric Services, 55(2), 174–179.

    Article  PubMed  Google Scholar 

  • Rosenheck, R. (2006). Outcomes, costs, and policy caution: A commentary on the cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Archives of General Psychiatry, 63, 1074–1076.

    Article  PubMed  Google Scholar 

  • Rosenheck, R., Perlick, D., Bingham, S., et al. (2003). Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. Journal of the American Medical Association, 290(20), 2693–2702.

    Article  PubMed  CAS  Google Scholar 

  • Schneider, E. C., Zaslavsky, A. M., & Epstein, A. M. (2002). Racial disparities in the quality of care for enrollees in medicare managed care. Journal of the American Medical Association, 287(10), 1288–1294.

    Article  PubMed  Google Scholar 

  • Shern, D., Robinson, P., Giard, J., & Vargo, A., et al. (2005). Evaluation of Florida’s Medicaid Managed Mental Health Plans: Year 8 Report Tampa, FL: Louis de la Parte Florida Mental Health Institute, University of South Florida.

    Google Scholar 

  • Svarstad, B. L., Shireman, T. I., & Sweeney, J. K. (2001). Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatric Services, 52, 805–811.

    Article  PubMed  CAS  Google Scholar 

  • Tandon, R. (1998). In conclusion, does antipsychotic treatment modify the long-term course of schizophrenic illness? Journal of Psychiatric Research, 32, 251–253.

    Article  PubMed  CAS  Google Scholar 

  • Thieda, P., Beard, S., Richter, A., & Kane, J. (2003). An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatric Services, 54(4), 508–516.

    Article  PubMed  Google Scholar 

  • Valenstein, M., Blow, F. C., Copeland, L. A., Mcarthy, J. F., et al. (2004). Poor antipsychotic adherence among patients with schizophrenia: Medication and patient factors. Schizophrenia Bulletin, 30(2), 255–264.

    PubMed  Google Scholar 

  • Vanelli, M., Burstein, P., & Crammer, J. (2001). Refill patterns of atypical and conventional antipsychotic medication at a national retail pharmacy chain. Psychiatric Services, 52, 1248–1250.

    Article  PubMed  CAS  Google Scholar 

  • Weiden, P., Aquila, R., & Standard, J. (1996). Atypical antipsychotic drugs and long-term outcome in schizophrenia. Journal of Clinical Psychiatry, 57(Suppl. ll), 53–60.

    PubMed  CAS  Google Scholar 

  • Weiden, P. J., Kozma, C., Grogg, A., & Locklear, J. (2004). Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatric Services, 55(8), 886–891.

    Article  PubMed  Google Scholar 

  • Weiden, P. J., & Olfson, M. (1995). Cost of relapse in schizophrenia. Schizophrenia Bulletin, 21, 419–429.

    PubMed  CAS  Google Scholar 

  • Weiden, P., & Zygmunt, A. (1997). Medication noncompliance in schizophrenia. Part I. Assessment. Journal of Practical Psychiatry and Behavioral Health, 3, 106–110.

    Google Scholar 

  • Wyatt, R. J., Henter, I., Leary, M. C., & Taylor, E. (1995). An economic evaluation of schizophrenia. Social Psychiatry and Psychiatric Epidemiology, 30, 196–205.

    PubMed  CAS  Google Scholar 

  • Ziguras, S. J., Klimidis, S., Lambert, T. J. R., & Jackson, A. C. (2001). Determinants of anti-psychotic medication compliance in a multicultural population. Community Mental Health Journal, 37(3), 273–283.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Mental Health Law & Policy—MHC 2735, Louis de la Parte Florida Mental Health Institute, University of South Florida, Tampa, FL, USA

    Marion A. Becker

  2. Department of Mental Health Law & Policy—MHC 2603, Louis de la Parte Florida Mental Health Institute, University of South Florida, Tampa, FL, USA

    M. Scott Young

  3. Department of Mental Health Law & Policy—MHC 2625G, Louis de la Parte Florida Mental Health Institute, University of South Florida, Tampa, FL, USA

    Ezra Ochshorn

  4. Department of Psychiatry, University of Wisconsin-Madison, Madison, WI, USA

    Ronald J. Diamond

Authors
  1. Marion A. Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Scott Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ezra Ochshorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ronald J. Diamond
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marion A. Becker.

Additional information

This paper was previously presented at the Academy Health Research Meeting: Becker, M.A., (June, 2005). Antipsychotic medication in schizophrenia: What is the impact of adherence on treatment outcomes. Paper presented at the Academy Health Research Meeting, Boston, M.A.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Becker, M.A., Young, M.S., Ochshorn, E. et al. The Relationship of Antipsychotic Medication Class and Adherence with Treatment Outcomes and Costs for Florida Medicaid Beneficiaries with Schizophrenia. Adm Policy Ment Health 34, 307–314 (2007). https://doi.org/10.1007/s10488-006-0108-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10488-006-0108-5

Keywords

Search

Navigation